Global Breast Cancer Market, By Therapy (Targeted Therapy, Hormonal Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By End-Users (Hospitals and Clinics), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

Global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022, growing at a CAGR of 9.8% during the forecast period from 2022 to 2032.

The most prevalent disorder in the population, with an increasing prevalence in women, is Breast Cancer. The symptoms include the development of lumps, changes in the size and shape of the breast, fluid leakage from the nipple, and itchy, scaly, red spots on the skin. It also exacerbates disease symptoms like bone pain, lymph node swelling, breathing issues, and many more.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• Breast Cancer Remains One of the World’s Deadliest Maladies: Breast cancer remains one of the world’s deadliest forms, and early diagnosis and effective treatments remain key elements in survival.
• Screening and Early Detection: Thanks to advances in mammography and other screening methods, early cancer detection rates and outcomes have seen substantial improvements. This early detection has improved survival rates as well as treatment outcomes.
• Personalised Medicine: Breast cancer treatments have increasingly turned towards personalized medicine, tailoring therapies according to genetic and molecular markers found within tumor cells for better efficacy while simultaneously decreasing side effects.
• Targeted Therapies: Targeted therapies such as HER2 inhibitors and CDK4/6 inhibitors have shown great promise in improving outcomes of certain subtypes of breast cancer by targeting specific proteins that play key roles.
• Immunotherapy: Immunotherapy treatments like immune checkpoint inhibitors are currently being explored as possible treatment solutions for breast cancer, providing potential new options.

Therapy Analysis

Based on therapy, the market for breast cancer is segmented into Targeted Therapy, Hormonal Therapy, Surgery, Radiation therapy, Biologic therapy, and Chemotherapy. The targeted therapy segment is the most lucrative in the global breast cancer market, with a projected CAGR of 9.8%. With rising market demands and societal disorder, the breast cancer market has experts with more experience in treatments, including cutting-edge produced therapies. The market share is growing as a result of enhanced treatment options, diagnosis of breast cancer, and more research and technology in breast cancer medicine.

The greatest market for targeted therapy is the breast cancer market, where usage of the therapy has increased as a result of higher production, better performance, technological advancement, as well as new drug launches that are contributing to the growth of the breast cancer market. Drugs used in targeted therapy include Kadcyla, Afinitor, Lynparza, and Zortress. With recent regulatory approvals, immunotherapy also gained a larger market share in the breast market.

Distribution Channel Analysis

By distribution channel, the market is divided into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. The hospital pharmacies segment is estimated to be the most lucrative segment in the global breast cancer market, owing to the patients’ increased reliance on chemotherapy-related drugs.

Throughout the forecast period, the treatment market for breast cancer is expected to rise as a result of increasing patient demand for various pharmaceuticals and improved accessibility to such products in hospital pharmacies. The major market shareholders in online pharmacies are attributed to increasing software development in hospitals and higher online prescriptions in hospitals, which stimulate the market for breast cancer with more online pharmacies and better connectivity throughout the projected period.

End-User Analysis

Based on end-user, the breast cancer market is segmented into hospitals and clinics. The emergency clinics and facilities fragment ruled the market for disease diagnostics and represented the biggest income portion of around 50.2% in 2020. Hospitals typically administer various diagnostic tests such as mammograms, ultrasounds, and biopsies to accurately assess the extent and stage of breast cancer.

Once diagnosed, patients may receive treatments like surgery, chemotherapy, radiation therapy, hormone therapy, or targeted therapy. Clinics on the other hand are typically specialized facilities dedicated solely to diagnosing and treating breast cancer; they may offer more specialized diagnostic and treatment options like genetic testing or clinical trials for new treatments.

Key Market Segments

Based on Therapy

• Targeted Therapy
• Hormonal Therapy
• Surgery
• Radiation therapy
• Biologic therapy
• Chemotherapy

Based on Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Based on End-User

• Hospitals
• Clinics

Drivers

Increase In Breast Cancer Cases in The Population

Breast cancer is one of the most common cancers identified in women globally, and its prevalence is increasing. The World Health Organization estimates that more than 2 million new instances of breast cancer were discovered globally in 2020, ranking it as the fifth most common cancer overall.

Improve Cutting-edge Technologies Created for The Treatment Of Breast Cancer

Research and technology have enabled the development of cutting-edge treatments for breast cancer, such as targeted therapies and immunotherapies. These treatments offer improved efficacy and reduced side effects compared to traditional chemotherapy, which will demand more modern efficient therapies.

Restraints

A Side Effect of The Treatment for Breast Cancer

Adverse effects of treatments include things like nausea, diarrhea, mouth ulcers, skin conditions, high blood pressure, gastrointestinal issues, and many more. These factors could make it difficult for the market to expand in size as a result of the severity of the adverse effects, which could also make people feel weaker. The market size may also change due to increased adverse events associated with immunotherapy and targeted chemotherapy.

High Development Costs

Finding new drugs and therapies for breast cancer is a lengthy and expensive process, which may limit the number of companies willing to invest. Furthermore, high development costs often lead to high drug prices which in turn limit patient access to treatment.

Opportunity

Increased Government Initiative

Developing treatments using cutting-edge technologies to improve patient health and increased support from governments of various regions in advancing development and research in pharmaceuticals for treating breast cancer are two examples of increased government support. Improved reimbursement policies allow more people to choose therapy and benefit from the treatments and medications that are available to enhance life quality.

Enhanced Development and Research

Breast cancer is a significant public health concern, with an estimated 2.3 million new cases diagnosed worldwide each year. Research and development (R&D) in the breast cancer market is focused on improving the detection, diagnosis, and treatment of breast cancer.

One area of R&D is focused on improving screening and detection methods. Mammography is currently the most commonly used screening tool, but it has limitations, particularly in women with dense breast tissue. Research is ongoing to develop more accurate and sensitive screening methods, such as breast MRI and 3D mammography. Additionally, researchers are exploring the use of biomarkers to detect breast cancer, including genetic markers and proteins.

Another area of R&D is focused on improving the accuracy of a breast cancer diagnosis. While mammography and biopsy are currently used to diagnose breast cancer, there is room for improvement in terms of accuracy and reducing the need for invasive procedures. Researchers are exploring the use of imaging techniques, such as contrast-enhanced mammography and ultrasound, as well as liquid biopsies that can detect cancer cells in the blood.

R&D is also focused on developing new and improved treatments for breast cancer. While surgery, radiation, and chemotherapy are currently used to treat breast cancer, there is a need for more targeted and less toxic therapies. Researchers are exploring the use of targeted therapies, such as HER2 inhibitors and hormone therapy, as well as immunotherapy and gene therapy.

Additionally, there is ongoing research into preventing breast cancer. Lifestyle changes, such as diet and exercise, have been shown to reduce the risk of breast cancer, and researchers are exploring the use of chemoprevention drugs to reduce the risk of developing breast cancer in high-risk women.

Overall, the breast cancer market is a dynamic area of research, with ongoing efforts to improve screening, diagnosis, and treatment of the disease. As discoveries are made, they will continue to improve patient outcomes and reduce the impact of breast cancer on individuals and society as a whole.

Trends

The ongoing R&D efforts for the discovery and marketing of effective medications for the treatment of breast cancer are one of the most pervasive trends in the worldwide market. The urgent need for the discovery of cutting-edge therapies for better outcomes remains unmet as the number of people with breast cancer continues to rise worldwide.

Sanofi, one of the major participants in the breast cancer therapeutics market, has been working on R&D projects to create new oral therapies for metastatic breast cancer.

Regional Analysis

Geographically speaking, North America retains the top spot in the industry with a rising market share for breast cancer. In 2022, North America held a share of 37% revenue share in the breast cancer market. Increased government action plans in developing new drugs developments, increased efficacy of the medications, and increased results contribute to market growth. Advanced developed technologies in the market and a growing proportion of treatments for the treatment of breast cancer with an increasing population help to propel the market growth.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

Emerging key players are focused on a variety of strategic policies to develop their respective businesses in foreign markets. The dominance of a small number of major businesses involved in the sales of oncology treatments is one of the fundamental features of the competitive marketplace of the global market. AstraZeneca, Pfizer Inc., Novartis AG, Genentech (F. Hoffmann-La Roche Ltd), and others are among them. These businesses, taken as a whole, hold the lion’s portion of the market thanks to their diverse and strong product lines of medications for the treatment of breast cancer.

These businesses also carry out cutting-edge research and development to provide medications for breast cancer treatment. For instance, Kadcyla, Xeloda, Perjeta, and Herceptin are only a few of the potent breast cancer treatments offered by Genentech (F. Hoffmann-La Roche Ltd).

Listed below are some of the most prominent breast cancer industry players.

 Market Key Players

• Mylan Laboratories
• AstraZeneca
• Celltrion
• Bristol-Myers Squibb
• Fresenius Kabi
• Eisai Co. Ltd
• Baxter Healthcare Corporation
• GlaxoSmithKline
• Pfizer Inc.
• Halozyme Inc.
• Merck & Co
• Kyowa Kirin
• Sanofi
• Novartis AG
• Eli Lilly and Company
• Genentech
• Other Key Players

Recent Developments

• In September 2020: After getting clearance for such Abbreviated New Drug Registration from (USFDA) U.S. Federal Drug Administration, the Alliance of Natco Pharma with Lupin debuted Lapatinib Tablets, 250mg, in the U.S. in September 2020. Natco will be the first manufacturer to market Lapatinib Tablets with 250mg.
• In June 2020: Pertuzumab, trastuzumab, and hyaluronidase, collectively known as Phesgo, were created in June of 2020 for use as an intramuscular injection to treat HER2-positive breast cancer patients.

Report Scope